A New Toolkit for Wisconsin Pharmacy Teams to Combat the Opioid Epidemic
by Hope E. Schier, 2024 PharmD Candidate, Kate J. Hartkopf, PharmD, BCACP, William J. Peppard, PharmD, BCPS, FCCM
"In 2022, the Wisconsin Department of Justice announced the final approval of an agreement with the nation’s three major pharmaceutical distributors (Cardinal, McKesson, and AmerisourceBergen) and Johnson & Johnson relating to their role in the opioid epidemic.1 According to 2021 Wisconsin Act 57, 70% of the settlement funding will be allocated to counties and municipalities that participated in the litigation, and the Department of Health Services (DHS) will receive the remaining funds. County governments that receive funds will be focused on core abatement strategies (Figure 1).2 These core strategies integrate well with pharmacy services and within communities."
Keywords: Analgesics, Opioid, Pharmacists, Wisconsin, Cities, Goals, Government Employees, Harm Reduction, Local Government, Opioid Epidemic, Public Health, Societies, Pharmaceutical, Opioid-Related Disorders, Naloxone, Pharmaceutical Services, Patient Care Team, Pharmaceutical Preparations, Patient Care
2024 January/February Table of Contents
"In 2022, the Wisconsin Department of Justice announced the final approval of an agreement with the nation’s three major pharmaceutical distributors (Cardinal, McKesson, and AmerisourceBergen) and Johnson & Johnson relating to their role in the opioid epidemic.1 According to 2021 Wisconsin Act 57, 70% of the settlement funding will be allocated to counties and municipalities that participated in the litigation, and the Department of Health Services (DHS) will receive the remaining funds. County governments that receive funds will be focused on core abatement strategies (Figure 1).2 These core strategies integrate well with pharmacy services and within communities."
Keywords: Analgesics, Opioid, Pharmacists, Wisconsin, Cities, Goals, Government Employees, Harm Reduction, Local Government, Opioid Epidemic, Public Health, Societies, Pharmaceutical, Opioid-Related Disorders, Naloxone, Pharmaceutical Services, Patient Care Team, Pharmaceutical Preparations, Patient Care
2024 January/February Table of Contents